According to a new report by Polaris Market Research, the global large molecule drug substance CDMO market was valued at USD 53.79 billion in 2025 and is projected to reach USD 102.36 billion by 2034, expanding at a CAGR of 7.41% over the forecast period. Growt0068 is underpinned by rising global approvals of biologic drugs, increasing healthcare expenditure, and accelerating adoption of single-use and continuous bioprocessing technologies across key end-use categories.

What Is Driving Large Molecule Drug Substance CDMO Market Growth?

Demand is climbing as global biologic drug approvals converge with rising healthcare expenditure and a growing share of biologics in total pharmaceutical spending. Pharmaceutical and biotech firms are prioritizing specialized manufacturing infrastructure, pushing CDMO adoption across monoclonal antibody and recombinant protein production. Polaris analysts note that U.S. CMS projections put health spending at USD 5.6 trillion in 2025, climbing to USD 8.6 trillion by 2033, positioning the biologics segment for sustained growth through 2034, with biopharmaceutical companies emerging as the largest end-user contributor and the biosimilar segment posting the fastest incremental gains.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/large-molecule-drug-substance-cdmo-market

Key Trends Shaping the Large Molecule Drug Substance CDMO Industry

Large-Scale Mammalian Manufacturing Capacity Coming Online

Major capacity investments are reaching commercial operation. In July 2026, Lonza confirmed that its new large-scale mammalian manufacturing asset in Visp, Switzerland, successfully commenced active commercial operations, reinforcing Europe's position in global biologics manufacturing capacity.

U.S. Market Entry Through Strategic Acquisition

Capacity expansion is increasingly happening through acquisition rather than greenfield build. In June 2026, Samsung Biologics announced its entry into the U.S. market with a USD 353 million acquisition of GSK's Rockville, Maryland manufacturing facility, adding 60,000 liters of capacity and bringing its total global capacity to 845,000 liters as part of its "3D Expansion Strategy."

Reshoring of Biologics Manufacturing Capacity

Domestic capacity investment is accelerating amid supply chain resiliency concerns. In September 2025, Hans Scientific announced a USD 2 billion investment to enhance U.S. biologics CDMO capacity, including injectable and lyophilization plants, reflecting the broader industry trend toward reshoring and localized drug production.

Market Segmentation: Breaking Down the Large Molecule Drug Substance CDMO Market

Polaris segments the large molecule drug substance CDMO market by product, service, source, end user, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Product

The biologics segment led with a 72.4% share in 2025, fueled by high demand for monoclonal antibodies and recombinant proteins. The biosimilar segment is expected to grow at the highest CAGR, driven by patent expirations of blockbuster biologics and greater adoption of lower-cost biosimilars.

By Service

Contract manufacturing dominated the market in 2025, supported by large-scale production requirements and robust infrastructure at established CDMOs. Contract development is expected to grow at an 11.5% CAGR, driven by increasing demand for early-stage process development and analytical support.

By Source

The mammalian segment led with a 58.7% share in 2025 due to its adaptability for developing complex biologics like monoclonal antibodies and recombinant proteins. The microbial segment is expected to post the highest CAGR, given its cost-effectiveness and quicker production cycles for enzymes and recombinant proteins.

By End User

Biopharmaceutical companies dominated the market in 2024, owing to large-scale biologics production and strong pipeline development. Biotechnology companies are anticipated to expand at the highest CAGR, fueled by rising biologics and biosimilar development among emerging biotech firms.

Regional Outlook: Where Is Large Molecule Drug Substance CDMO Demand Growing Fastest?

North America held the largest share at 42.8% in 2025, due to the strong presence of established biopharmaceutical companies and advanced CDMO infrastructure, with the U.S. leading through high biopharmaceutical company density and reshoring investment. Asia Pacific is projected to grow at a 10.9% CAGR, the fastest of any region, driven by rising biologics manufacturing investments in China and India — China leads the region through growing local CDMO capacity and government policies favoring pharmaceutical outsourcing. Europe held substantial market share by 2034, supported by strong biosimilar adoption and well-established biopharma hubs in the UK and Germany.Competitive Landscape: Leading Large Molecule Drug Substance CDMO Companies

Key players profiled in the report include Thermo Fisher Scientific Inc., Eurofins Scientific SE, Wuxi Biologics, Samsung Biologics Co., Ltd., Catalent, Inc., AGC Biologics, and Lonza Group, who are focusing on biologics and biosimilar manufacturing capacity, partnerships with international biopharma companies, and single-use bioprocessing technology to strengthen market position across the biologics and biopharmaceutical company segments outlined above. Recent moves include Lonza's July 2026 commercial launch of its Visp mammalian manufacturing asset and Samsung Biologics' June 2026 U.S. market entry acquisition, both aimed at deepening share across North America and Europe.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching biologics manufacturing capacity, this report benchmarks large molecule drug substance CDMO market share, segment-level pricing, and forecast data — by product, service, source, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing biologics CDMO vendors, investors sizing entry points in biosimilar manufacturing, and strategy teams tracking microbial platforms as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

manga-market

smart-home-market

retinol-market

asia-pacific-laundry-detergent-market

gas-detection-equipment-market

advanced-driver-assistance-systems-adas-market

leading-graph-database-market-players-enabling-real-time-relationship-analytics

bio-based-polymers-market

container-transshipment-market